Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder.
Business Wire › February 10, 2011
Linked as:
Extract
Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder.
Metabolic Replacement Therapy Designed to Prevent Severe Brain Damage, Early Mortality in Infants with Molybdenum Cofactor Deficiency (MoCD) Type A
CHESHIRE, Conn. -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that it has purchased patents and ...See the full content of this document
Sponsored links
